Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Grosse

Showing results (1-10 of 272) with videos related to

Pageof 28
Sort By:
Healthcare (Basel, Switzerland)|October 17, 2015
When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their RelativesScott D Grosse
American Journal of Preventive Medicine|November 21, 2017
How Economic Findings Can Inform Prevention Research in Cardiovascular DiseaseScott D Grosse
Child Development|March 25, 2010
Late-treated phenylketonuria and partial reversibility of intellectual impairmentScott D Grosse
The Journal of Pediatrics|February 4, 2005
Does newborn screening save money? The difference between cost-effective and cost-saving interventionsScott D Grosse
American Journal of Obstetrics and Gynecology|March 9, 2010
What is the value for money of prenatal carrier screening for spinal muscular atrophy? Too soon to sayScott D Grosse
Healthcare (Basel, Switzerland)|December 25, 2015
Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic FibrosisScott D Grosse
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 17, 2018
Is universal tumor testing for Lynch syndrome cost-effective? It depends!Scott D Grosse
Thrombosis Research|August 6, 2016
Cost-of-illness models for venous thromboembolism: One size does not fit allScott D Grosse
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY thresholdScott D Grosse
Thrombosis and Haemostasis|December 14, 2011
Incidence-based cost estimates require population-based incidence data. A critique of Mahan et alScott D Grosse
Pageof 28

Showing results (1-10 of 272) with videos related to

Sort By:
Pageof 28
Healthcare (Basel, Switzerland)|October 17, 2015
When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their RelativesScott D Grosse
American Journal of Preventive Medicine|November 21, 2017
How Economic Findings Can Inform Prevention Research in Cardiovascular DiseaseScott D Grosse
Child Development|March 25, 2010
Late-treated phenylketonuria and partial reversibility of intellectual impairmentScott D Grosse
The Journal of Pediatrics|February 4, 2005
Does newborn screening save money? The difference between cost-effective and cost-saving interventionsScott D Grosse
American Journal of Obstetrics and Gynecology|March 9, 2010
What is the value for money of prenatal carrier screening for spinal muscular atrophy? Too soon to sayScott D Grosse
Healthcare (Basel, Switzerland)|December 25, 2015
Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic FibrosisScott D Grosse
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 17, 2018
Is universal tumor testing for Lynch syndrome cost-effective? It depends!Scott D Grosse
Thrombosis Research|August 6, 2016
Cost-of-illness models for venous thromboembolism: One size does not fit allScott D Grosse
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY thresholdScott D Grosse
Thrombosis and Haemostasis|December 14, 2011
Incidence-based cost estimates require population-based incidence data. A critique of Mahan et alScott D Grosse
Pageof 28